Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|November 7, 2014
Using the LGR5 Protein as a Biomarker in Thyroid Cancer
Author(s)Brittany N. Bohinc, MD
Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.
Advertisement
Clinical Pearls
Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.
- LGR5 is a protein that marks cancer stems cells. It is known to be important in colorectal cancer and gastric cancer.
- Using two methods, researchers found that LGR5 was highly expressed in papillary thyroid cancer.
- LGR5 in thyroid cancer is associated with lymph node number, lymph node metastases, tumor size, T stage, N stage, extrathyroidal extension, lymphovascular invasion, and macroscopic extension.
- LGR5 could be used as a biomarker for novel therapeutics or risk stratification for surgery.
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Elinzanetant Gets Priority Review for VMS From Breast Cancer Endocrine Therapy
5